Liraglutide ELISA
| Specifications | |
|---|---|
| Reactivity: | Human |
| Sample Type: | Plasma, Serum |
| Sample Size: | 100 µL |
| Sensitivity: | 40 ng/mL |
| Detection Range: | 40 - 2,560 ng/mL |
| Assay Time: | 2 hr 30 min |
Product Description
The Liraglutide ELISA is for the quantitative determination of Liraglutide (Victoza®/Saxenda®) in human serum and plasma. For Research Use Only. Not for use in diagnostic procedures.
Liraglutide (NN2211) is a derivative of a human incretin (metabolic hormone), glucagon-like peptide-1 (GLP-1) that is used as a long-acting glucagon-like peptide-1 receptor agonist, binding to the same receptors as the endogenous metabolic hormone GLP-1 that stimulates insulin secretion. Marketed under the brand name Victoza®, it is an injectable drug developed by Novo Nordisk for the treatment of type 2 diabetes.
In 2015, Novo Nordisk began marketing a separate strength in the U.S. and E.U. under the brand name Saxenda® as a treatment for adults who are obese or overweight with at least one weight-related comorbid condition. This ELISA Kit has been calibrated against commercially-sourced referenced therapeutic product Victoza® Injection.
- Catalog Number
07-LIRHU-E01-AL - Supplier
ALPCO - Size
- Shipping
Blue Ice
